Vitamin K2 (as MK-7)

Introduction to Vitamin K2 (MK-7) For decades, Vitamin K was viewed almost exclusively through the lens of hematology. Named after the German word Koagulation, its primary recognized function was the synthesis of blood-clotting factors in the liver. However, modern nutritional biochemistry has uncovered a profound distinction between Vitamin K1 (phylloquinone) and Vitamin K2 (menaquinone). While K1 is abundant in leafy greens and swiftly utilized by the liver for coagulation, Vitamin K2—specifically the long-chain menaquinone-7 (MK-7) form—travels far beyond the liver.

Found naturally in fermented foods like natto, MK-7 is a highly bioavailable, fat-soluble vitamin that acts as a biological traffic cop for calcium. By activating specific proteins in the body, MK-7 ensures that calcium is directed into the skeletal system where it is needed, and kept out of the vascular system where it can cause harm. Today, MK-7 is widely regarded as an essential daily nutrient for long-term bone mineral density and cardiovascular longevity.

The Biochemical Mechanism: Gamma-Carboxylation To understand why MK-7 is so critical, one must look at the enzymes it supports. MK-7 functions as an essential cofactor for the enzyme gamma-glutamyl carboxylase (GGCX). This enzyme is responsible for a structural modification called 'carboxylation' on specific vitamin K-dependent proteins.

When proteins like osteocalcin (in bone) and Matrix Gla Protein (in blood vessels) are first synthesized by the body, they are 'undercarboxylated' and biologically inactive. They lack the chemical 'claws' needed to grab onto calcium ions. When MK-7 enters the cell, it allows GGCX to convert glutamic acid residues on these proteins into gamma-carboxyglutamic acid (Gla) residues. This transformation activates the proteins, giving them a high affinity for binding free calcium. Without adequate MK-7, these proteins remain inactive, leading to a state where calcium floats freely in the bloodstream, unable to be integrated into bone and prone to depositing in arterial walls.

Clinical Evidence for Bone Health The most robust clinical data supporting Vitamin K supplementation centers on skeletal health. According to an extensive evidence review by Examine.com, which analyzed 142 references including 24 trials and 13 meta-analyses, Vitamin K exerts a 'Moderate Improvement' (Grade B evidence) on Bone Mineral Density (BMD).

Across 13 studies involving 1,049 participants, supplementation consistently improved markers of bone health. This benefit extends to highly vulnerable populations; an analysis of 9 studies featuring 4,800 participants showed moderate improvements in BMD for osteoporotic patients. Furthermore, 2 studies involving 327 participants demonstrated that Vitamin K helps preserve bone mineral density during menopause, a critical window where the drop in estrogen typically triggers rapid bone resorption.

The clinical standard dose for bone health using the MK-7 form specifically ranges from 100 to 375 mcg per day. Because MK-7 activates osteocalcin, it directly facilitates the integration of calcium into the hydroxyapatite matrix of the bone, increasing its structural density and resistance to fracture.

Cardiovascular Implications: The Calcium Paradox One of the most compelling reasons consumers seek out MK-7 is to address the 'Calcium Paradox'—a phenomenon where aging individuals suffer from a simultaneous lack of calcium in their bones (osteoporosis) and an excess of calcium in their arteries (arteriosclerosis).

Mechanistically, MK-7 resolves this paradox by activating Matrix Gla Protein (MGP) in the vascular smooth muscle. MGP is the most potent known inhibitor of vascular calcification. When activated by MK-7, MGP binds to free calcium in the blood, preventing it from crystallizing into plaque within the arterial walls.

However, it is important to note the current state of the clinical literature. While the mechanistic rationale is flawless, Examine.com currently grades the effect of Vitamin K on reducing Calcium Scores in Chronic Kidney Disease patients as a Grade D (No effect), based on 4 studies. This suggests that while MK-7 may prevent future calcification, its ability to reverse existing calcification or significantly alter calcium scores in short-term trials remains unproven. It is best viewed as a long-term preventative measure rather than an acute cardiovascular treatment.

The Crucial Synergy with Vitamin D3 As highlighted by functional medicine specialists at the Cleveland Clinic, Vitamin D and Vitamin K are frequently, and correctly, taken together. Vitamin D3 is a fat-soluble vitamin that promotes the intestinal absorption of calcium and regulates bone growth. When you take Vitamin D3, your body absorbs significantly more calcium from your diet.

However, Vitamin D3 does not dictate where that calcium goes. If you have high levels of Vitamin D3 but are deficient in Vitamin K2, you risk absorbing large amounts of calcium that cannot be properly bound to the bone matrix due to inactive osteocalcin. This excess calcium may then deposit in soft tissues or the kidneys. By pairing D3 with MK-7, you create a complete biological pathway: D3 opens the door for calcium to enter the bloodstream, and MK-7 provides the blueprint that directs it safely into the skeleton.

Pharmacokinetics: Why MK-7 is the Superior Form When shopping for Vitamin K, you will frequently see Vitamin K1, Vitamin K2 as MK-4, and Vitamin K2 as MK-7. MK-7 is widely considered the superior form for supplementation due to its unique pharmacokinetics.

Because of its long polyisoprenoid side chain (seven isoprene units), MK-7 is highly lipophilic. While K1 is rapidly cleared by the liver within hours, MK-7 is packaged into VLDL and LDL cholesterol particles and circulated throughout the body. This allows it to reach extrahepatic tissues like bone and blood vessels with high efficiency.

Most importantly, MK-7 has an extraordinary half-life of approximately 72 hours. This means that a relatively low once-daily dose (e.g., 90 to 100 mcg) allows the vitamin to accumulate to steady, therapeutic levels in the blood. In contrast, MK-4 has a half-life of just 1 to 2 hours, requiring multiple daily doses and massive quantities (often 15 to 45 mg—thousands of times higher than MK-7) to achieve similar clinical outcomes.

Debunking Myths: What MK-7 Doesn't Do In the supplement industry, ingredients are often marketed as panaceas. It is vital to look at the clinical data to understand what MK-7 does not do. According to Examine.com's rigorous grading system, Vitamin K has a Grade D (No effect) rating for several commonly claimed benefits: Bruising: Despite its role in blood clotting, supplementing extra Vitamin K does not reduce bruising in healthy individuals. Blood Pressure: MK-7 does not act as a vasodilator or lower blood pressure. Metabolic Health: It has no significant effect on C-Reactive Protein (CRP) or Adiponectin levels, meaning it is not an effective standalone treatment for systemic inflammation or Type 2 Diabetes.

Dosage Guidelines and Safe Supplementation The Adequate Intake (AI) for Vitamin K is set at 120 mcg/day for adult males and 90 mcg/day for adult females. However, clinical studies utilizing MK-7 for bone health typically employ doses ranging from 100 mcg to 375 mcg per day.

Because MK-7 is a fat-soluble vitamin, it must be taken with food that contains dietary fat to ensure proper intestinal absorption. Taking it on an empty stomach will severely limit its bioavailability.

Currently, there is no established Upper Tolerable Limit (UL) for Vitamin K, as toxicity from high dietary or supplemental intake has not been observed in healthy populations. However, this does not mean massive doses are necessary; the 72-hour half-life of MK-7 ensures that doses in the 100-200 mcg range are more than sufficient to fully carboxylate osteocalcin and MGP.

Safety, Contraindications, and Drug Interactions While generally safe for the healthy population, MK-7 has one critical, life-threatening contraindication: Warfarin (Coumadin).

Warfarin is an anticoagulant medication that works specifically by inhibiting the Vitamin K cycle (blocking the VKOR enzyme). By taking Vitamin K2, you are directly providing the antidote to the medication, which can rapidly reverse the blood-thinning effect and lead to fatal blood clots. Anyone on Warfarin or similar Vitamin K antagonist blood thinners must strictly avoid MK-7 supplements unless explicitly directed and monitored by their cardiologist.

Additionally, individuals with hepatobiliary dysfunction (liver or gallbladder issues) may have impaired ability to absorb fat-soluble vitamins. Drugs that block fat absorption, such as orlistat or colesevelam, will also block the absorption of MK-7, and the two should be taken several hours apart.